Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of colchicine and non-enteric coated aspirin, alone or combined, in improving cardiovascular outcomes in high-risk adults with type 2 diabetes. This Phase 3 trial focuses on people aged 55 to 80 years who have type 2 diabetes and are at increased risk of cardiovascular events but have no prior history of coronary artery disease-related clinical events. The study aims to prevent serious heart-related problems such as heart attack, stroke, or urgent hospitalizations. Participants are randomly assigned to one of several groups receiving either colchicine 0.5 mg once daily, aspirin 40 mg non-enteric coated tablet twice daily, both, or matching placebos. Those eligible for aspirin therapy are grouped accordingly, while others ineligible for aspirin receive colchicine or placebo. The study uses a factorial design and quadruple masking to fairly evaluate the effects of these drugs over time. During the study, participants are monitored for up to 60 months for cardiovascular events including death, heart attacks, strokes, and hospitalizations for heart conditions. Cognitive function is also assessed yearly using MoCA scores. Researchers collect data on safety, adherence, and outcomes through regular follow-ups to understand how these treatments affect heart health and overall wellbeing in people with type 2 diabetes.
Actively Recruiting
Researchers are evaluating the long-term effects of lidocaine infusions given during and after surgery to reduce moderate or severe chronic post-surgical pain in adult women undergoing elective breast cancer surgery. This large, international, randomized, double-blind trial aims to detect a meaningful reduction in chronic pain one year after surgery and also assesses safety, pain relief, opioid use, nerve-related pain symptoms, psychological health, and quality of life. Participants receive either a lidocaine infusion starting with an intravenous bolus after anesthesia induction, continuing with an intraoperative intravenous infusion, and followed by a post-operative subcutaneous infusion for up to 24 hours. The lidocaine dosing is adjusted by lean body weight with a cap, while the comparison group receives a saline placebo infusion following the same schedule. Day-case surgeries receive only the intraoperative treatments without the post-operative infusion. During the trial, participants will be monitored for pain severity, opioid consumption, nerve-related symptoms, psychological distress, physical functioning, quality of life, safety events, and health care costs up to one year after surgery. The primary outcome is the incidence of moderate or severe chronic post-surgical pain reported at one year. Assessments include patient-reported outcomes, pain scores at 24 hours postoperatively, and opioid use at various timepoints. The total participation duration extends up to one year after surgery.